Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Cemdisiran
Regeneron UK Limited
Paroxysmal Nocturnal Hemoglobinuria
1 trial -
Cemdisiran, Pozelimab
Lacuna Pharma Pty Ltd
Paroxysmal nocturnal hemoglobinuria (PNH)
1 trial -
Cemiplimab
Regeneron UK Limited
Squamous Cell Carcinoma (SCC)
1 trial -
Cemiplimab
Regeneron UK Limited
Cutaneous Squamous Cell Carcinoma
7 trials -
Cemiplimab
Regeneron UK Limited
Recurrent Lung Non-Small Cell Carcinoma
1 trial -
Cemiplimab
Regeneron UK Limited
Cutaneous Squamous Cell Carcinoma (CSCC)
1 trial -
Cendakimab
Celgene Europe Limited
Eosinophilic esophagitis
1 trial -
Cenerimod
Viatris Pharmaceuticals Co.,
Lupus Erythematosus, Systemic
2 trials -
Cenerimod 4 mg
Viatris Pharmaceuticals Co.,
Systemic lupus erythematosus
1 trial -
Cenerimod 4 mg, Cenerimod matching placebo
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
Cenerimod matching placebo, Cenerimod 4 mg
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
Cenestin 0.3 mg Tablets
Teva Pharma GmbH
Hot Flashes
1 trial -
Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo 15mg tablets, venglustat GZ402671 - SAR402671, Placebo 6mg tablets, Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo for Cerezyme, Cerezyme 400 Units Powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671
Sanofi-aventis Healthcare Pty Ltd
Gaucher's disease type III
1 trial -
Cervarixβ’
GlaxoSmithKline
Infections, Papillomavirus
1 trial -
Cetirizine
BRIGHT MINDS BIOSCIENCES INC.
COVID-19
1 trial -
Cetuximab
Amgen
Metastatic Colorectal Cancer
1 trial -
Champix
Hospital Authority, Hong Kong
Tobacco Use Disorder
1 trial -
Chemotherapy
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia
1 trial -
Chemotherapy
United Therapeutics Europe Ltd
Transitional Cell Carcinoma of Ureter
1 trial -
Chemotherapy
The First People's Hospital of Lianyungang
Endometrial Cancer
1 trial -
Chemotherapy
International Peace Maternity and Child Health Hospital
Non Small Cell Lung Cancer
1 trial -
Chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
Chemotherapy + avelumab followed by avelumab + talazoparib
Pfizer
Ovarian Cancer
1 trial -
Chemotherapy drug
Chinese PLA General Hospital
Gastric Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources